Corvus Pharmaceuticals (FRA:C17) FFO


FRA:C17 Corvus Pharmaceuticals Inc FRA:C17
32 GF Score
Price €11.27
! 1 Warning Sign
View Full Analysis

What is Corvus Pharmaceuticals FFO?

FFO (Funds from operations) only applies to REITs.

FRA:C17
32GF Score
Corvus Pharmaceuticals Inc FRA:C17
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corvus Pharmaceuticals Business Description

Other Exchanges CRVS:USAC17:Germany
Address 901 Gateway Boulevard, Third Floor, South San Francisco, CA, USA, 94080
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
32GF Score

Get the complete analysis for FRA:C17

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.27
Price